BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31497024)

  • 1. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.
    Qi J; Hymel D; Nelson CG; Burke TR; Rader C
    Front Immunol; 2019; 10():1994. PubMed ID: 31497024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically Programmed Bispecific Antibodies in Diabody Format.
    Walseng E; Nelson CG; Qi J; Nanna AR; Roush WR; Goswami RK; Sinha SC; Burke TR; Rader C
    J Biol Chem; 2016 Sep; 291(37):19661-73. PubMed ID: 27445334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically programmed bispecific antibodies that recruit and activate T cells.
    Cui H; Thomas JD; Burke TR; Rader C
    J Biol Chem; 2012 Aug; 287(34):28206-14. PubMed ID: 22761439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
    Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
    Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer.
    Wang Y; Zhang Y; Sun H; Chen J; Yang H; Zhong Z; Xiao X; Li Y; Tang Y; Lu H; Tang X; Zhang M; Wu W; Zhou S; Yang J
    Int Immunopharmacol; 2023 Oct; 123():110686. PubMed ID: 37499397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirecting cytotoxic T cells with chemically programmed antibodies.
    Qi J; Rader C
    Bioorg Med Chem; 2020 Dec; 28(24):115834. PubMed ID: 33166926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies in cancer immunotherapy.
    Rader C
    Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
    Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
    Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
    Cyr MG; Mhibik M; Qi J; Peng H; Chang J; Gaglione EM; Eik D; Herrick J; Venables T; Novick SJ; Courouble VV; Griffin PR; Wiestner A; Rader C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.
    Thompson S; Dessi J; Self CH
    MAbs; 2009; 1(4):348-56. PubMed ID: 20068406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
    Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
    Front Immunol; 2021; 12():663379. PubMed ID: 33936101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.
    Avanzino BC; Prabhakar K; Dalvi P; Hartstein S; Kehm H; Balasubramani A; Boudreau AA; Buelow B; Chang K; Davison LM; Iyer S; Kalwit V; Lewis Wilson K; Malik-Chaudhry HK; Pierson W; Pineda G; Rangaswamy US; Saiganesh S; Schellenberger U; Ugamraj HS; Yabut RD; Buelow R; Chapman J; Trinklein ND; Harris KE
    Oncoimmunology; 2022; 11(1):2113697. PubMed ID: 36016696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
    Cho BK; Roy EJ; Patrick TA; Kranz DM
    Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.